Reference for REGDANVIMAB. Search for REGDANVIMAB

AI searches containing REGDANVIMAB

REGDANVIMAB

Regdanvimab

Monoclonal antibody

Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against

Regdanvimab

COVID-19 drug development

Preventative and therapeutic medications for COVID-19 infection

issued an emergency use authorization for pemivibart in March 2024. Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody

COVID-19 drug development

COVID-19_drug_development

List of therapeutic monoclonal antibodies

Regavirumab mab human cytomegalovirus glycoprotein B cytomegalovirus infection Regdanvimab Regkirona mab human spike protein receptor binding domain (RBD) of SARS-CoV-2

List of therapeutic monoclonal antibodies

List_of_therapeutic_monoclonal_antibodies

ZMapp

Experimental treatment for Ebola virus disease

Maftivimab Nirsevimab† Odesivimab Pemivibart Rafivirumab§ Regavirumab§ Regdanvimab Sevirumab† Sipavibart Sotrovimab Suptavumab Tixagevimab† (+cilgavimab)†

ZMapp

COVID-19 pandemic in Nepal

Bamlanivimab/etesevimab Bamlanivimab Etesevimab Bebtelovimab Casirivimab/imdevimab Regdanvimab Sarilumab Sotrovimab Tixagevimab/cilgavimab Tocilizumab Small molecule

COVID-19 pandemic in Nepal

COVID-19_pandemic_in_Nepal

ATC code J06

Pharmaceutical drug classification

Tixagevimab and cilgavimab J06BD04 Ansuvimab J06BD05 Sotrovimab J06BD06 Regdanvimab J06BD07 Casirivimab and imdevimab J06BD08 Nirsevimab J06BD09 Sipavibart

ATC code J06

ATC_code_J06